The Underlying Cause of Suicides and
Homicides with SSRI Antidepressants:
Is It the Drugs, the Doctors, or the Drug Companies?
How a dysfunctional medical-pharmaceutical complex causes and perpetuates unnecessary harm.
Reports of unusual, severe reactions with selective
serotonin reuptake inhibitor antidepressant drugs (SSRIs) emerged soon after
the first SSRI, Prozac, was introduced in 1988. One of my own patients, a
woman with a mild depressive disorder and no history of major psychiatric
symptoms, became psychotic after just three days on Prozac. Another woman,
a highly successful attorney, developed such severe panic attacks that she
couldn't work. Such cases were reported so frequently that Congress held hearings
on the issue in the early 1990s. But because the hearings got no further than
arguing whether SSRIs cause suicidal and homicidal behavior or not, and never
looked at the underlying causes, nothing was accomplished.
I have never doubted that SSRIs (Prozac, Paxil,
Zoloft, Celexa, Lexapro, Luvox, Effexor, Sarafem) can provoke impulsive, violent
behavior. Now, sixteen years after the first reports, British regulatory authorities
have acted against the use of SSRIs in children because of an increased incidence
of suicide. This forced the U.S. Food and Drug Administration to take a second
look. In early February 2004, a FDA advisory committee heard powerful testimony
from bereaved parents and medical experts and issued a call for stronger warnings
on the labels of these drugs. The FDA is considering it.
Even if the FDA acts, will such warnings make
any difference? Not likely. As the FDA has learned, adding warnings to package
inserts does little to improve how doctors prescribe drugs.1-3
Doctors kept prescribing Rezulin and Seldane inappropriately despite added
warnings, and patients continued dying until the drugs were withdrawn. About
20% of all medications ultimately require additional "black-box"
warnings about dangerous side effects discovered after the drugs' approvals,1
yet despite these additional warnings, doctors' prescribing methods remain
poor and the incidence of medication-caused hospitalizations and deaths remains
Merely adding warnings to package inserts is
inadequate because once doctors begin prescribing a drug, they don't read
every updated package insert of every drug they use. Doing so would take hours,
and package inserts are long and written in tiny, barely readable script,
so new warnings are easily overlooked. Moreover, it usually takes years for
such warnings to be added to package inserts, during which time doctors continue
prescribing the drugs to millions of people. The fact is, most doctors rely
on information provided by the drug companies' legions of sales representatives
who accentuate the positive and downplay the negative.
What should be done? The answer is obvious:
look at why these reactions are occurring and impose appropriate solutions.
My book, Over
Dose: The Case Against The Drug Companies (Tarcher/Putnam 2001)4
laid it out and, for doing so, received excellent reviews including the recommendation
of the Journal of the American Medical Association. Here is a more
succinct explanation of why good drugs cause so much unnecessary harm, and
why the medical-pharmaceutical complex allows it to happen again and again. The Drug Companies
irst rule: it's all about sales. Making profits is the overriding ethic of pharmaceutical companies. What maximizes sales? Marketing that impresses doctors. Although patients like you take the medications, pay the pharmacies, and take the risks, it is doctors who decide which drug and what dosage is used. Doctors are the final decision makers, and once a prescription is written, you have no say in the matter. If your doctor prescribes 50 mg of Zoloft for you, you cannot tell your pharmacist to give you a lower dosage or that you want to get Paxil or Effexor instead.
The Drug Companies
Doctors determine which drugs will succeed and
which will fail. Drug companies know this and know how to impress doctors
with: 1) claims of superior effectiveness; 2) easy-to-use drugs. Superior
effectiveness means being able to claim that your drug is better than its
competitors in some way. It's very helpful, for example, for a drug company
to be able to boast that "our drug helps 72% of patients, yet our competitor's
helps only 64%." Although these numbers may have little meaning when
it comes to treating individuals, the numbers impress doctors. To achieve
superior numbers, drug companies use stronger and stronger drug doses in their
studies in order to elicit any little advantage over competitors that they
can then market vigorously to doctors. They publish the studies they want
the healthcare community to see and untold the ones they don't.
Drug companies also know that doctors like drugs
that are easy to prescribe. One-size-fits-all drugs fit the bill, because
their dosages are easy to remember and doctors don't have to take the time
to select different doses for different patients. This goes against the basic
medical principle of individual variation: that different people require and
tolerate different doses of medications (just as with coffee and alcohol).
But such methods allow drug companies to promote their drugs with such boasts
as "no adjustment needed for the elderly," as if that's a good thing.
It isn't -- older people almost always require much lower drug doses -- but
most doctors unquestioningly accept drug company guidelines.
Today's pharmaceutical industry marketing strategy
is: Make it strong and keep it simple. This is why Prozac was introduced with
a one-size-fits-all starting dose of 20 mg, even though the manufacturer knew
that 54% of patients responded to just 5 mg, a 75%-lower dose that caused
fewer side effects.5 Other SSRIs with unnecessarily
strong starting doses soon followed.
Strong drug doses work for some people, but
they are a sure-fire recipe for major side effects in others, yet the drug
companies develop drug after drug in this manner. This is why SSRIs cause
sexual dysfunctions in as many as 50% of patients.6-8
Side effects such as anxiety, agitation (akathisia), insomnia, and panic attacks
are common and can become so severe that they impair cognitive functioning
and judgment, leading to impulsive, destructive behavior by people who never
acted in such a way before.9-13
Doctors and SSRI Antidepressants
Patients have the mistaken impression that doctors understand SSRI drugs. Most doctors don't.
The drug companies have marketed SSRI antidepressants
vigorously not only to psychiatrists, who are supposed to have some expertise
with these drugs, but also to family practitioners, pediatricians, gynecologists,
internal medicine specialists, and anyone else who can pen a prescription.
But this doesn't mean that they possess in-depth knowledge of SSRIs or their
actions and toxicities. Many doctors don't know the difference between major
and minor (dysthymic) depressions and that the latter responds to much lower
SSRI doses. Many doctors don't understand bipolar (manic-depressive) disorder
and that overly strong SSRI doses can trigger manic reactions.
Even worse, many doctors think SSRIs are the
best treatment for anxiety symptoms. They aren't. For immediate relief of
anxiety, Xanax, Valium, and other benzodiazepines are fast-acting and safe
if used in moderation. SSRIs have no immediate anxiety-reducing effects. To
the contrary, they can actually provoke anxiety. SSRIs also frequently cause
insomnia that is so intractable, doctors prescribe sleep-enhancing drugs,
further complicating treatment.
So why do doctors prescribe SSRIs for anxiety
symptoms? Because if taken for awhile -- at a low dosage -- SSRIs can sometimes
reduce the development of anxiety symptoms. When used properly, SSRIs can
help panic and obsessive-compulsive disorders, but such use means starting
with a very low dose and explaining that the benefits may not be seen for
weeks. Doctors should also explain to patients that these drugs can worsen
anxiety initially. If this happens, patients should contact the doctor, and
the dosage should be lowered. Do doctors actually warn patients about this?
Rarely. Most doctors don't understand it themselves.
Even psychiatrists are often appallingly ignorant
about how SSRIs work. This was made clear in a January 5, 2004, article in
The New York Times titled "A Doctor's Toxic Shock."14
A doctor taking Wellbutrin herself described her reaction: "I developed
insomnia, agitation and tremors... panic attacks started... I needed every
ounce of energy to concentrate at work.... Sometimes I felt paranoid, and
I wondered if I was delusional. When I wasn't working, I was curled in a fetal
position, contemplating whether I should hospitalize myself."
This was a serious reaction, exactly like those
that drive some people to violence. Yet the doctor had no clue that it was
a dose-related reaction to the very drug she had prescribed for herself. What
did she do? Exactly what she and other doctors tell patients to do: stick
it out until the drug's benefits kick in. This is ridiculous, dangerous advice,
but it's the medical mainstream's party line. Indeed, the doctor described
talking to colleagues, who were similarly perplexed by her symptoms. It is
very disturbing to think that there are psychiatrists out there who can't
recognize the most basic adverse effects of these antidepressants. Every psychiatrist
I asked about this immediately identified the symptoms as SSRI side effects
and recommended discontinuing the drug or at least decreasing the dosage,
so at least some psychiatrists know what they are doing. But not enough, apparently.
There is no excuse for not recognizing SSRI
reactions. There is extensive literature on the dangers with SSRIs 9-13,
15-26, and anxiety and agitation are listed
as side effects in the package inserts of most SSRI drugs and Wellbutrin (which
although not an SSRI, can cause anxiety.) So it is alarming that so many intelligent,
capable doctors are so confused when typical SSRI side effects develop. Yet,
if these doctors are relying on the information provided by drug companies
and their 90,000 sales reps and drug company-underwritten, expenses-paid seminars
and conferences, maybe it isn't so surprising after all.
Medical educators such as Dr. Jerry Avorn at Harvard and Dr. Roger Jelliffe at the University of Southern California have long sought better training for doctors about medications. Presently, most students get one course that broadly covers the basics on hundreds of drugs, but lacks any depth and fails to teach critical analysis. Raymond L. Woosley, Vice President of Health Services at the University of Arizona wrote to me:
"Only about fifteen of the medical schools today teach formal courses in clinical pharmacology, which is the discipline that emphasizes interindividual variability in response to drugs. This small effort will never counter the overwhelming message from the drug industry that one dosage is all that is needed and everyone will respond nicely without side effects."27
Dr. Woosley would like to make many changes.
So would I. Dr. Jelliffe tried, but was told that medical students' schedules
were already filled with more important classes. That's odd, because doctors'
most frequent intervention is writing prescriptions. So what could be more
important than learning to prescribe drugs properly and recognize side effects
Meanwhile, the drug companies have penetrated every corner of medical schools and hospitals today. Medical school faculties and hospital staff are highly reliant on drug company money. The situation is so extreme that in 2000, the editor-in-chief of the New England Journal of Medicine published a disturbing yet all-too-true article titled "Is Academic Medicine for Sale?" Dr. Marcia Angell wrote:
"Academic medical institutions are themselves growing increasingly beholden to [the drug] industry.... Some academic institutions have entered into partnerships with drug companies to set up research centers and teaching programs in which students and faculty members essentially carry out industry research... Young physicians learn that for every problem, there is a pill (and a drug company representative to explain it)." 28
The drug companies are so entrenched in the
education of medical students and the continuing education of doctors, it
is no stretch for me to claim that we now have a "medical-pharmaceutical
complex." In it, doctors' education and information is so controlled
by the drug industry, doctors don't even know how limited their information
is. New generations of doctors are taught that they know everything important
about medications, when in fact they don't.
Thus, doctors aren't informed about obvious
SSRI reactions and therefore don't warn patients. When reactions occur, doctors
cannot identify them. They tell patients to stick with the drugs or increase
the doses, making things worse. When patients complain about side effects,
many doctors deny, deny, deny. Doctors must decide whether their allegiance
is to their patients or to their medications. As I wrote in Over
Dose, many doctors over-identify with their drugs, so when the drugs cause
side effects, doctors get defensive rather than simply seeing side effects
as something that they and their patients can solve together. The Drugs
Should Prozac, Paxil, Zoloft, Celexa, Lexapro, Luvox, Effexor, and Sarafem be withdrawn? Some people think so, claiming that SSRIs demonstrate no greater effectiveness than placebo.
I stand squarely on the side that believes SSRI
drugs are helpful to millions of people, including children. I get letters
from people who feel very differently, but my experience and my reading of
the medical literature convince me that SSRIs have a role in treating depression
and other conditions.
This isn't to say that SSRI drugs are perfect.
Any drug that produces benefit can also cause harm. People vary widely in
their responses to drugs. This is why it is so important to treat each person
individually and, except in acute situations, to start with doses low enough
to avoid problems. Such doses may be 5 mg of Prozac, 10 mg of Paxil, 25 mg
of Zoloft, 37.5 or 75 mg of Effexor, etc. Some people are ultra sensitive
to SSRIs and do well on as well as 2.5 mg of Prozac or 12.5 mg of Zoloft or
equivalently tiny doses of other SSRIs.
If after a week or two, no benefit and no side
effects are seen, the doses can be gradually increased. I call this the "Start
Low, Go Slow" method. By starting low and increasing gradually, you are
guaranteed to get the right amount of medication for you. In this way, risks
are minimized. This safety-first method is essential for side effect-prone
drugs like SSRIs. Doctors should always start with low doses for people who
are old, small, taking other medications, or who have a history of sensitivities
to medications. But the start-low go-slow approach is also appropriate for
anyone who wants to minimize medication risks.
This amounts to a lot of people. When I was
still treating patients, I explained the benefits and risks of antidepressants
and asked patients whether they would prefer starting with a standard, drug
company-recommended dose or a lower, safer, proven-effective dose. More than
80% preferred the low-dose approach. Many never needed the full drug company-recommended
Omitted Information = Denial of Your Right
of Informed Consent
The start-low go-slow approach make perfect sense and is easy to initiate -- if drug companies provide information about the lowest, safest drug doses in their package inserts and the Physicians' Desk Reference. Most often, they don't. Without such information, doctors and patients remain mystified when side effects strike. Many doctors mistake side effects for symptoms of the depressive disorder, and rather than reducing the medication, increase it, thereby exacerbating the reactions. People suffer. Needlessly.
Information is key to inform consent. The American Medical Association Code of Medical Ethics states:
"The patient's right of self-decision can be effectively exercised only if the patient possesses enough information to enable an intelligent choice.... The physician has an ethical obligation to help the patient make choices from among the therapeutic alternatives consistent with good medical practice."29
If drug companies don't provide you with information
about the lowest, safest, effective drug doses, they are denying your right
of informed consent. If drug companies don't give doctors full information
about SSRI side effects, doctors cannot inform you, and your rights are further
infringed. If doctors don't read the information that the drug companies do
provide, your quality of treatment and rights of informed consent are again
Studies have shown that only a small percentage of patients get enough information in doctors' offices to fulfill informed consent.30 With SSRI antidepressants, such negligence can be lethal.
A Six-Point Solution
In a recent newsletter ("An Open Letter to the U.S. Food and Drug Administration on Serotonin-Enhancing Antidepressants," Feb. 2004), I offered a 6-point solution to the SSRI problem:
1. Except for acute situations, patients must be started at the lowest, safest, effective doses of SSRI antidepressants.
2. Drug companies must define these doses, provide information in package inserts and the PDR, and produce pills and liquids that make using low doses possible. Drug companies must make public all of their data on any drug to be used in humans.
3. Doctors must be trained in the safe use of SSRI antidepressants. Classes and certification should be required for prescribing these drugs. This training should include some basic knowledge of pharmacokinetics, the science of drug metabolism which clearly shows that some patients are slow metabolizers of SSRIs and will develop high blood concentrations even with modest SSRI doses. If doctors understood pharmacogenetics better, they wouldn't be surprised that some people need very low doses of SSRIs and other medications.
4. Doctors must follow patients closely and warn patients about possible SSRI side effects. New patients should be seen frequently until doses are adjusted properly and side effects, if they occur, are handled effectively. Doctors should select SSRIs that come in low doses or as liquids, which allow careful, gradual dose titration.
5. Patients, including parents of children-patients, must be fully informed about the potential risks of SSRIs. Patients can play a critical role in recognizing early signs of serious side effects. The failure to provide adequate information constitutes a denial of patients' rights of informed consent and places patients at unnecessary risk.
6. The FDA must initiate policies requiring drug companies to develop the lowest, safest doses of not only SSRI antidepressants, but all drugs. The FDA must compel drug companies to add warnings to their package inserts promptly when new side effects are reported. For serious adverse effects like SSRI reactions, the FDA must compel manufactures to send warning letters to each doctor. Because even these methods are sometimes ineffective, the FDA must require doctors to report all SSRI reactions and monitor these reports closely, issuing a public statement every six months.
What is the FDA suggesting instead? Stronger
warnings in package inserts -- a strategy the FDA knows is inadequate.
My 6-point solution would allow drug companies to continue marketing SSRIs, allow doctors to continue prescribing them in appropriate situations, and allow patients to obtain the benefits of SSRIs with minimum risk. This is what needs to be done not only with SSRIs, but with many top-selling drugs. But will it? Not likely in today's medical-pharmaceutical complex in which drug companies set their own prices, collect profits far beyond any other industry, and exert enormous influence on doctors, medical schools, Congress and the FDA -- and society itself.
The irony is that my proposals would not only
help patients, but restore some confidence in the doctor-patient relationship.
Even the drug companies would benefit, because by providing better information
about side effects and lower, safer medication doses, side effects would be
fewer and, if occurring, would be handled properly. This is a much better
scenario than today's SSRI scandal that has further tarnished the drug companies'
image and hurts SSRI sales.
Above all, the saddest thing about SSRI-related suicides and homicides is that they are preventable. Most side effects are preventable. When drugs and doses are matched to individual needs and tolerances, benefits are maximized and risks are minimized. Except for acute situations, a start-low go-slow approach guarantees that each person gets the right amount of medication for them, thereby reducing the frequency and severity of side effects. I've been talking about this for thirty years and writing about it for fifteen. But that's not how things are done in today's medical-pharmaceutical complex, where pharmaceutical sales are paramount and patients' safety isn't.
1. Lasser, KE, Alan, PD, Woolhandler, SJ, Himmelstein, DU, Wolfe, SM, Bor, DH. Timing of New Black Box Warnings and Withdrawals for Prescription Medications. JAMA 2002;287:2215-2220.
2. Moore, TJ, Psaty, BM, Furberg, CD. Time to act on drug safety. JAMA 1998;279(19):1571-3.
3. Ray, WA, Griffin, MR, Avorn, J. Evaluating Drugs after Their Approval for Clinical Use. New England Journal of Medicine 1993;329:2029-32.
4. Cohen, JS. Over Dose: The Case Against The Drug Companies. Prescription Drugs, Side Effects, and Your Health. Tarcher/Putnam, New York: October 2001.
5. Wernicke, JF, Dunlop, SR, Dornseif, BE, et al. Low-dose fluoxetine therapy for depression. Psychopharmacology Bulletin 1988;24(1):183-188.
6. Hirschfeld, RM. Management of sexual side effects of antidepressant therapy. Journal of Clinical Psychiatry 1999;60(Suppl 14):27-30.
7. Modell, JG, Katholi, CR, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clinical Pharmacology and Therapeutics 1997;61(4):476-87.
8. Jacobsen, FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Journal of Clinical Psychiatry 1992;53(4):119-22.
9. Medawar, C, Herxheimer, A, Bell, A, et al. Paroxetine, Panorama, and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance. International Journal of Risk & Safety in Medicine 2002;15:161-169.
10. Glenmullen, J. Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants with Safe, Effective Alternatives. Simon and Schuster, March 2000.
11. Donovan, S, Clayton, A, Beeharry, M, et al. Deliberate self-harm and antidepressant drugs. Investigation of a possible link. British Journal of Psychiatry, 2000;177:551-6.
12. Teicher, MH, Glod, C, Cole, JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 1990;147(2):207.
13. Healy, D. The Antidepressant Era. Harvard University Press, Sept. 1997.
14. Gartrell, N. A Doctor's Toxic Shock. New York Times, Jan. 5, 2003:nytimes.com
15. FDA statement regarding the antidepressant Paxil for pediatric population. U.S. Food and Drug Administration, June 19, 2003:www.fda.gov -- accessed 9/18/O3.
16. Louie, AK, Lewis, TB, Lannon, MD. Use of low-dose fluoxetine in major depression and panic disorder. Journal of Clinical Psychiatry 1993;54(1):435-438.
17. Waechter, F. Paroxetine must not be given to patients under 18. BMJ, June 14, 2003;326:1282.
18. Harris, G. Debate Resumes on the Safety of Depression's Wonder Drugs. New York Times, Aug. 7, 2003:nytimes.com.
19. Hickling, L. Questions Persist concerning Prozac's Role in Suicide Risk. Www.drkoop.com Health News, May 11, 2000: www.drkoop.com/dyncon/article.asp?at=N&id=11009.
20. Fichter, CG, Jobe, TH, Braun, BG. Does fluoxetine have a therapeutic window? Lancet 1991;338.
21. Anderson GM; Segman RH; King RA. Serotonin and suicidality: the impact of fluoxetine administration. II: Acute neurobiological effects. Israel Journal of Psychiatry and Related Sciences, 1995, 32(1):44-50.
22. Lancon, C, Bernard, D, Bougerol, T. [Fluoxetine, akathisia and suicide]. Encephale, 1997 May-Jun, 23(3):218-23. Abstract.
23. Liu, CY, Yang, YY, et al. Fluoxetine-related suicidality and muscle aches in a patient with poststroke depression [letter]. Journal of Clinical Psychopharmacology, 1996 Dec, 16(6):466-7.
24. Jackson, A. Drug Turned Loving Man into a Killer, Says Judge. Sidney Morning Herald, Fri., May 25, 2001:www.smh.com.au/
25. Donovan, S, Clayton, A, et al. Deliberate self-harm and antidepressant drugs. Investigation of a possible link. British Journal of Psychiatry, 2000;177:551-6.
26. Rogers, L, Waterhouse, R. Prozac Makers Told to Warn of Side-Effects. The Sunday Times [Britain], July 8, 2001:www.sunday-times.co.uk/news.
27. Personal communication via email, Apr. 29, 2002, 4:49 EDT, WoosleyR@aol.com.
28. Angell, M. Is Academic Medicine for Sale? New England Journal of Medicine 2000;342:1516-18.
29. American Medical Association Council on Ethical and Judicial Affairs. Code of Medical Ethics, 1998-1999 Edition. American Medical Association, Chicago, IL.
30. Braddock, CH, Edwards, KA, et al. Informed Decision Making in Outpatient Practice: Time to Get Back to Basics. JAMA 1999;282:2313-20.
NOTE TO READERS: The purpose of this E-Letter is solely informational and educational. Theinformation herein should not be considered to be a substitute forthe direct medical advice of your doctor, nor is it meant to encourage the diagnosis or treatment of any illness, disease, or other medical problem by laypersons. If you are under a physician's care for any condition, he or she can advise you whether the information in this E-Letter is suitable for you. Readers should not make any changes in drugs, doses, or any other aspects of their medical treatment unless specifically directed to do so by their own doctors.
If you have questions about your medications or medical care, Dr. Cohen is available for consultation at his office or by telephone.
If you find this article informative, please tell your friends, family members, colleagues, and doctors about www.MedicationSense.com and the free MedicationSense E-Newsletter.